Radiation-induced second malignancies after involved-node radiotherapy with deep-inspiration breath-hold technique for early stage Hodgkin Lymphoma: A dosimetric study

Radiation Oncology

Volumn 9, Issue 1, 2014, Pages

  Schneider, Uwe ^a,b   Sumila, Marcin ^b   Robotka, Judith ^a   Weber, Damien ^c   Gruber, Günther ^b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b Institute for Radiotherapy   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; ATTRIBUTABLE RISK; BREAST CANCER; BREATH HOLDING; BREATHING; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CARCINOGENESIS; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; DEEP INSPIRATION BREATH HOLD INVOLVED NODE RADIOTHERAPY; DOSIMETRY; ESOPHAGUS CANCER; FEMALE; HODGKIN DISEASE; HUMAN; INVOLVED NODE RADIOTHERAPY; LUNG CANCER; MAJOR CLINICAL STUDY; OSTEOSARCOMA; RADIATION DOSE FRACTIONATION; RADIATION INDUCED NEOPLASM; SECOND CANCER; SOFT TISSUE SARCOMA; STOMACH CANCER; THREE DIMENSIONAL CONFORMAL RADIOTHERAPY; THYROID CANCER; VOLUMETRIC ARC THERAPY; WHOLE BODY CT; YOUNG ADULT;

ADULT; AGED, 80 AND OVER; BREAST NEOPLASMS; BREATH HOLDING; FEMALE; HODGKIN DISEASE; HUMANS; INHALATION; LYMPHATIC IRRADIATION; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY; RADIOMETRY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; RISK FACTORS; YOUNG ADULT;

EID: 84896802942     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-9-58     Document Type: Article

References (28)

1. Fermé C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Diviné M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vié B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M, EORTC-GELA H8 Trial Chemotherapy plus involved-field radiation in early-stageHodgkin's disease. N Engl J Med 2007, 357(19):1916-1927. 10.1056/NEJMoa064601, 17989384, EORTC-GELA H8 Trial.
2. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, Schwartz CL, Leisenring W, Robison LL, Childhood Cancer Survivor Study Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006, 355(15):1572-1582. 10.1056/NEJMsa060185, 17035650, Childhood Cancer Survivor Study.
3. Castellino SM, Geiger AM, Mertens AC, Leisenring WM, Tooze JA, Goodman P, Stovall M, Robison LL, Hudson MM. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood 2011, 117(6):1806-1816. 10.1182/blood-2010-04-278796, 3056636, 21037086.
4. Weber DC, Peguret N, Dipasquale G, Cozzi L. Involved-node and involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supra-diaphragmatic Hodgkin lymphoma: a comparative planning study. Int J Radiat Oncol Biol Phys 2009, 75(5):1578-1586. 10.1016/j.ijrobp.2009.05.012, 19596171.
5. Campbell BA, Hornby C, Cunninghame J, Burns M, MacManus M, Ryan G, Lau E, Seymour JF, Wirth A. Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy. Ann Oncol 2012, 23(5):1259-1266. 10.1093/annonc/mdr439, 21980193.
6. Weber DC, Johanson S, Peguret N, Cozzi L, Olsen DR. Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage hodgkin lymphoma in female patients. Int J Radiat Oncol Biol Phys 2011, 81(2):490-497. 10.1016/j.ijrobp.2010.05.035, 20800383.
7. Paumier A, Ghalibafian M, Gilmore J, Beaudre A, Blanchard P, el Nemr M, Azoury F, al Hamokles H, Lefkopoulos D, Girinsky T. Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2012, 82(4):1522-1527. 10.1016/j.ijrobp.2011.05.015, 21705151.
8. Charpentier A-M, Conrad T, Sykes J, Ng A, Zhou R, Parent A, Coolens C, Tsang RW, Gospodarowicz MK, Sun A, Hodgson DC. Active breathing control for patients receiving mediastinal radiation therapy for lymphoma: Impact on normal tissue dose. Pract Radiat Oncol http://dx.doi.org/10.1016/j.prro.2013.07.015.
9. Hälg RA, Besserer J, Schneider U. Systematic measurements of whole-body dose distributions for various treatment machines and delivery techniques in radiation therapy. Med Phys 2012, 39(12):7662-7676. 10.1118/1.4767773, 23231314.
10. Hälg RA, Besserer J, Schneider U. Systematic measurements of whole-body imaging dose distributions in image-guided radiation therapy. Med Phys 2012, 39(12):7650-7661. 10.1118/1.4758065, 23231313.
11. Eich HT, Müller RP, Engenhart-Cabillic R, Lukas P, Schmidberger H, Staar S, Willich N. German Hodgkin Study Group. Involved-node radiotherapy in early-stage Hodgkin's lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG). Strahlenther Onkol 2008, 184(8):406-410. 10.1007/s00066-008-1882-7, 18956517.
12. Wong VY, Tung SY, Ng AW, Li FA, Leung JO. Real-time monitoring and control on deep inspiration breath-hold for lung cancer radiotherapy-combination of ABC and external marker tracking. Med Phys 2010, 37(9):4673-4683. 10.1118/1.3476463, 20964186.
13. Hoppe RT. Radiation therapy in the management of Hodgkin's disease. Semin Oncol 1990, 17(6):704-715.
14. Schneider U. Mechanistic model of radiation-induced cancer after fractionated radiotherapy using the linear-quadratic formula. Med Phys 2009, 36(4):1138-1143. 10.1118/1.3089792, 19472619.
15. Schneider U, Zwahlen D, Ross D, Kaser-Hotz B. Estimation of radiation-induced cancer from three-dimensional dose distributions: Concept of organ equivalent dose. Int J Radiat Oncol Biol Phys 2005, 61(5):1510-1515. 10.1016/j.ijrobp.2004.12.040, 15817357.
16. Schneider U, Kaser-Hotz B. Radiation risk estimates after radiotherapy: application of the organ equivalent dose concept to plateau dose-response relationships. Radiat Environ Biophys 2005, 44(3):235-239. 10.1007/s00411-005-0016-1, 16273381.
17. Schneider U, Stipper A, Besserer J. Dose-response relationship for lung cancer induction at radiotherapy dose. Z Med Phys 2010, 20(3):206-214. 10.1016/j.zemedi.2010.03.008, 20832008.
18. Schneider U, Sumila M, Robotka J, Gruber G, Mack A, Besserer J. Dose-response relationship for breast cancer induction at radiotherapy dose. Radiat Oncol 2011, 8(6):67.
19. Schneider U, Sumila M, Robotka J. Site-specific dose-response relationships for cancer induction from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy. Theor Biol Med Model 2011, 26(8):27.
20. Kellerer AM, Nekolla EA, Walsh L. On the conversion of solid cancer excess relative risk into lifetime attributable risk. Radiat Environ Biophys 2001, 40(4):249-257. 10.1007/s004110100106, 11820733.
21. Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002, 38(1):99-166. 10.1016/S0959-8049(01)00350-1, 11750846.
22. Hodgson DC, Gilbert ES, Dores GM, Schonfeld SJ, Lynch CF, Storm H, Hall P, Langmark F, Pukkala E, Andersson M, Kaijser M, Joensuu H, Fosså SD, Travis LB. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol 2007, 25(12):1489-1497. 10.1200/JCO.2006.09.0936, 17372278.
23. Hodgson DC, Koh ES, Tran TH, Heydarian M, Tsang R, Pintilie M, Xu T, Huang L, Sachs RK, Brenner DJ. Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer 2007, 110(11):2576-2586. 10.1002/cncr.23081, 17941006.
24. De Bruin ML, Sparidans J, van't Veer MB, Noordijk EM, Louwman MW, Zijlstra JM, van den Berg H, Russell NS, Broeks A, Baaijens MH, Aleman BM, van Leeuwen FE. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 2009, 27(26):4239-4246. 10.1200/JCO.2008.19.9174, 19667275.
25. Goodman KA, Toner S, Hunt M, Wu EJ, Yahalom J. Intensity-modulated radiotherapy for lymphoma involving the mediastinum. Int J Radiat Oncol Biol Phys 2005, 62:198-206. 10.1016/j.ijrobp.2004.08.048, 15850922.
26. Maraldo MV, Brodin NP, Aznar MC, Vogelius IR, Munck af Rosenschöld P, Petersen PM, Specht L. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma. Ann Oncol 2013, 24(8):2113-2118. 10.1093/annonc/mdt156, 23619032.
27. Fiandra C, Filippi AR, Catuzzo P, Botticella A, Ciammella P, Franco P, Borca VC, Ragona R, Tofani S, Ricardi U. Different IMRT solutions vs. 3D-conformal radiotherapy in early stage Hodgkin's Lymphoma: dosimetric comparison and clinical considerations. Radiat Oncol 2012, 7:186. 10.1186/1748-717X-7-186, 3502518, 23122028.
28. Cella L, Conson M, Pressello MC, Molinelli S, Schneider U, Donato V, Orecchia R, Salvatore M, Pacelli R. Hodgkin's lymphoma emerging radiation treatment techniques: trade-offs between late radio-induced toxicities and secondary malignant neoplasms. Radiat Oncol 2013, 8:22. 10.1186/1748-717X-8-22, 3641014, 23360559.